JP2025518638A5 - - Google Patents
Info
- Publication number
- JP2025518638A5 JP2025518638A5 JP2025513495A JP2025513495A JP2025518638A5 JP 2025518638 A5 JP2025518638 A5 JP 2025518638A5 JP 2025513495 A JP2025513495 A JP 2025513495A JP 2025513495 A JP2025513495 A JP 2025513495A JP 2025518638 A5 JP2025518638 A5 JP 2025518638A5
- Authority
- JP
- Japan
- Prior art keywords
- transposase
- protein
- vitro method
- nucleic acid
- aptamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341619P | 2022-05-13 | 2022-05-13 | |
| US63/341,619 | 2022-05-13 | ||
| EP22191966 | 2022-08-24 | ||
| EP22191966.5 | 2022-08-24 | ||
| PCT/EP2023/062736 WO2023218021A1 (en) | 2022-05-13 | 2023-05-12 | Use of transposases for improving transgene expression and nuclear localization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025518638A JP2025518638A (ja) | 2025-06-18 |
| JP2025518638A5 true JP2025518638A5 (https=) | 2026-04-08 |
Family
ID=86605260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025513495A Pending JP2025518638A (ja) | 2022-05-13 | 2023-05-12 | 導入遺伝子の発現および核局在化を改善するためのトランスポザーゼの使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4522735A1 (https=) |
| JP (1) | JP2025518638A (https=) |
| KR (1) | KR20250010025A (https=) |
| CN (1) | CN119487184A (https=) |
| AU (1) | AU2023269540A1 (https=) |
| CA (1) | CA3253152A1 (https=) |
| WO (1) | WO2023218021A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110047635A1 (en) * | 2006-08-28 | 2011-02-24 | University of Hawail | Methods and compositions for transposon-mediated transgenesis |
| CA3082450A1 (en) * | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| US12338453B2 (en) * | 2018-12-17 | 2025-06-24 | Consejo Superior De Investigaciones Científicas (Csic) | Method for the introduction of genetic information in cell by site-specific integration system |
| WO2020243085A1 (en) | 2019-05-24 | 2020-12-03 | The Trustees Of Columbia University In The City Of New York | Engineered cas-transposon system for programmable and site-directed dna transpositions |
| CN115968301A (zh) * | 2020-04-20 | 2023-04-14 | 综合Dna技术公司 | 优化的蛋白融合和接头 |
| MX2022015284A (es) * | 2020-06-05 | 2023-01-19 | Univ California | Composiciones y metodos para la edicion del epigenoma. |
| CA3173696A1 (en) * | 2020-07-17 | 2022-01-20 | Volker Sandig | Hyperactive transposons and transposases |
| AU2021403660A1 (en) | 2020-12-16 | 2023-07-06 | Universitat Pompeu Fabra | Programmable transposases and uses thereof |
-
2023
- 2023-05-12 KR KR1020247040630A patent/KR20250010025A/ko active Pending
- 2023-05-12 CN CN202380039707.0A patent/CN119487184A/zh active Pending
- 2023-05-12 AU AU2023269540A patent/AU2023269540A1/en active Pending
- 2023-05-12 EP EP23726939.4A patent/EP4522735A1/en active Pending
- 2023-05-12 JP JP2025513495A patent/JP2025518638A/ja active Pending
- 2023-05-12 CA CA3253152A patent/CA3253152A1/en active Pending
- 2023-05-12 WO PCT/EP2023/062736 patent/WO2023218021A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6946384B2 (ja) | 脂質ナノ粒子を含む医薬組成物 | |
| JP6921797B2 (ja) | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド | |
| CN109803977B (zh) | 核酸产品及其施用方法 | |
| EP3443086B1 (en) | Cas9 fusion molecules, gene editing systems, and methods of use thereof | |
| JP5902679B2 (ja) | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン | |
| TW202136509A (zh) | 用於基因編輯之經修飾引導rna | |
| US20200340012A1 (en) | Crispr-cas genome engineering via a modular aav delivery system | |
| JP2022507454A5 (https=) | ||
| JP2022540318A5 (https=) | ||
| JP2022519507A5 (https=) | ||
| JP2023534693A5 (https=) | ||
| JP2023554504A5 (https=) | ||
| JP2022545950A5 (https=) | ||
| EP4396340A1 (en) | Rna-guided genome recombineering at kilobase scale | |
| JP2026500040A (ja) | 複合体及びその使用 | |
| EP4543908A1 (en) | Compositions and methods for epigenetic editing | |
| CN117721096A (zh) | 重组人透明质酸酶变体及其应用 | |
| JP2025518638A5 (https=) | ||
| JP2023507034A5 (https=) | ||
| JP2024515113A (ja) | 重篤な疾患を処置するためのｂ細胞ベースのタンパク質工場の操作 | |
| JPWO2023120658A5 (https=) | ||
| JP2024507451A5 (https=) | ||
| JP2023553701A5 (https=) | ||
| Vavilis et al. | mRNA in the context of protein replacement therapy. Pharmaceutics 2023; 15: 166 | |
| CN117561331A (zh) | 用于产生经基因修饰的原代细胞的方法和组合物 |